Dr. Reddy's Laboratories RDY
US equityMarket cap rank #1259Drug Manufacturers - Specialty & GenericInfectious DiseaseCannabis & Hemp
$14.89 +$0.06 (+0.40%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $15.00 +0.74%
Open$14.88
Prev close$14.83
Day range$14.86 – $15.10
Volume1.75M
Market cap$12.41B
P/E (TTM)41.4
Dividend yield0.56%
RDY Stock News
Headlines matching Dr. Reddy's Laboratories or the RDY ticker, most recent first.
- Published on 09/30: RDY Shows Double Bottom, as Citi Upgrades Dr. Reddy's to Buy With Target Raised to 1,450 Rupees Positive
- Citigroup Upgrades Dr Reddy's Laboratories to Buy, Raises Price Target to $1450 Positive
- Morgans Sticks to Its Buy Rating for ReadyTech Holdings Ltd. (RDY)
- Jarden Remains a Buy on ReadyTech Holdings Ltd. (RDY)
- Shaw and Partners Keeps Their Buy Rating on ReadyTech Holdings Ltd. (RDY)
- Elara Securities India Downgrades Dr. Reddy's Laboratories to Reduce From Accumulate; Price Target Is INR1,283 Negative
- Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,740 From INR1,600, Keeps at Buy
- Shaw and Partners Reaffirms Their Buy Rating on ReadyTech Holdings Ltd. (RDY)
- BofA Securities Maintains Dr. Reddy's Laboratories(RDY.US) With Buy Rating, Cuts Target Price to $16.33 Negative
- Morgans Sticks to Their Buy Rating for ReadyTech Holdings Ltd. (RDY)
- Ord Minnett Keeps Their Buy Rating on ReadyTech Holdings Ltd. (RDY)
- Ord Minnett Sticks to Its Buy Rating for ReadyTech Holdings Ltd. (RDY)
- ReadyTech Holdings Ltd. (RDY) Receives a Buy From Shaw and Partners
- Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
- Dr. Reddy's Laboratories | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
No comments yet — be the first to weigh in on RDY.
Sign in to join the discussion.